Scarica l'app Stockscreener
71.84
1.84%
1.30
Dopo l'orario di chiusura:
71.90
0.06
+0.08%
Precedente Chiudi:
$70.54
Aprire:
$72
Volume 24 ore:
135.92K
Relative Volume:
1.21
Capitalizzazione di mercato:
$482.20M
Reddito:
Utile/perdita netta:
$-14.99M
Rapporto P/E:
-34.76
EPS:
-2.0665
Flusso di cassa netto:
$-10.01M
1 W Prestazione:
-3.22%
1M Prestazione:
-15.72%
6M Prestazione:
+32.99%
1 anno Prestazione:
-11.57%
Intervallo 1D:
$70.20
$73.99
Intervallo di 1 settimana:
$69.33
$73.99
Portata 52W:
$50.07
$124.82
Monopar Therapeutics Inc Stock (MNPR) Company Profile
Nome
Monopar Therapeutics Inc
Settore
Industria
Telefono
(847) 388-0349
Indirizzo
1000 SKOKIE BLVD SUITE 350, WILMETTE
Compare MNPR vs VRTX, REGN, MRNA, ARGX, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MNPR
Monopar Therapeutics Inc
|
71.84 | 482.20M | 0 | -14.99M | -10.01M | -2.0665 |
VRTX
Vertex Pharmaceuticals Inc
|
521.03 | 132.06B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
816.10 | 84.02B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
207.97 | 83.03B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
882.48 | 55.50B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
366.06 | 41.41B | 5.76B | 514.49M | 1.10B | 4.4813 |
Monopar Therapeutics Inc Stock (MNPR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-08-13 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2026-01-09 | Iniziato | Morgan Stanley | Overweight |
| 2025-11-14 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2025-11-10 | Iniziato | Leerink Partners | Outperform |
| 2025-10-13 | Iniziato | Barclays | Overweight |
| 2025-09-09 | Iniziato | BTIG Research | Buy |
| 2025-09-03 | Iniziato | Oppenheimer | Outperform |
| 2025-09-03 | Iniziato | Raymond James | Strong Buy |
| 2025-08-26 | Ripresa | H.C. Wainwright | Buy |
| 2025-07-07 | Iniziato | Cantor Fitzgerald | Overweight |
| 2025-06-23 | Iniziato | Chardan Capital Markets | Buy |
| 2025-03-19 | Ripresa | Piper Sandler | Overweight |
| 2025-01-10 | Iniziato | Piper Sandler | Overweight |
| 2024-10-11 | Iniziato | Rodman & Renshaw | Buy |
| 2021-01-28 | Iniziato | ROTH Capital | Buy |
Mostra tutto
Monopar Therapeutics Inc Borsa (MNPR) Ultime notizie
Form 4 Monopar Therapeutics Inc: Quan Anh Vu (CFO) For: 30 September - Investing.com Nigeria
Form 4 Monopar Therapeutics Inc: Andrew Cittadine (COO) For: 30 September - Investing.com Nigeria
Form 4 Monopar Therapeutics Inc: Chandler Robinson (Director, CEO) For: 30 September - Investing.com India
Form 4 Monopar Therapeutics Inc: Chandler Robinson (Director, CEO) For: 30 September - Investing.com Canada
Form 4 Monopar Therapeutics Inc: Quan Anh Vu (CFO) For: 30 September - Investing.com Canada
Form 4 Monopar Therapeutics Inc: Quan Anh Vu (CFO) For: 30 September - Investing.com UK
Monopar Therapeutics director Christopher Starr sells shares worth $659k - Investing.com
Monopar Therapeutics director Christopher Starr sells shares worth $659k By Investing.com - Investing.com Canada
Form 4 Monopar Therapeutics Inc For: 11 October By Investing.com - Investing.com Nigeria
Form 4 Monopar Therapeutics Inc For: 11 October By Investing.com - Investing.com Canada
Monopar Therapeutics stock faces insider selling after Q2 loss - AD HOC NEWS
Form 4 Monopar Therapeutics Inc For: 6 October By Investing.com - Investing.com Canada
Form 4 Monopar Therapeutics Inc For: 6 October By Investing.com - Investing.com Nigeria
After a $0.005-per-share option exercise, Monopar Therapeutics (MNPR) director sells 8,400 shares. - Stock Titan
180 shares cover CFO taxes as Monopar Therapeutics (MNPR) settles a 614-share stock grant. - Stock Titan
16,800 shares are proposed for sale by Monopar Therapeutics (MNPR) director Christopher Starr. - Stock Titan
Form 4 Monopar Therapeutics Inc For: 28 September By Investing.com - Investing.com Nigeria
Form 4 Monopar Therapeutics Inc For: 28 September By Investing.com - Investing.com South Africa
Form 4 Monopar Therapeutics Inc For: 28 September By Investing.com - Investing.com India
Form 4 Monopar Therapeutics Inc For: 28 September By Investing.com - Investing.com Canada
Form 4 Monopar Therapeutics Inc For: 28 September By Investing.com - Investing.com UK
Four share sales at $87.15 to $89.79: Monopar Therapeutics (MNPR) CEO also exercised options. - Stock Titan
Stock-option shares are proposed for sale by Chandler Robinson at Monopar Therapeutics (NASDAQ: MNPR). - Stock Titan
Monopar Therapeutics Is Maintained at Overweight by Barclays - Moomoo
MNPR Maintained by Barclays -- Price Target Raised to $145 - GuruFocus
Barclays Maintains Monopar Therapeutics(MNPR.US) With Buy Rating, Raises Target Price to $145 - Moomoo
Discipline and Rules-Based Execution in MNPR Response - Stock Traders Daily
Monopar Therapeutics shares technical analysis: $120.21 resistance in focus after rally - Traders Union
Monopar Therapeutics stock trades near record levels as investors react to insider selling and stron - ad-hoc-news.de
What's behind Monopar Therapeutics's latest 3.0% stock pullback? - Traders Union
Monopar Therapeutics director Kim Tsuchimoto sells $455,566 in shares By Investing.com - Investing.com Canada
Monopar Therapeutics (MNPR) director sells 4,090 shares after option exercises - Stock Titan
Monopar Therapeutics director Raymond Anderson sells $351,835 in stock By Investing.com - Investing.com Canada
Monopar (MNPR) insider sells at $110–113 after $30 option exercise - stocktitan.net
Will Monopar Therapeutics stock regain momentum as oversold conditions limit further selling? - Traders Union
Monopar Therapeutics director Raymond Anderson sells $351,835 in stock - Investing.com
Monopar director Kim Tsuchimoto sells $455k in common stock - Investing.com India
Monopar Therapeutics director Kim Tsuchimoto sells $455,566 in shares - Investing.com
Monopar director Kim Tsuchimoto sells $455k in common stock By Investing.com - Investing.com Nigeria
Monopar Therapeutics director Raymond Anderson sells $351k in stock By Investing.com - Investing.com Canada
Monopar Therapeutics Director Kim R. Tsuchimoto Executes Six-Tranche Stock Sale Under Rule 10b5-1 Plan - Kalkine Media
Monopar Therapeutics (MNPR) CMO uses plan to exercise options - stocktitan.net
Monopar Therapeutics director Raymond Anderson sells USD 349,125 of common shares - Bitget
Monopar Therapeutics (MNPR) director sells 3,142 shares in plan trade - stocktitan.net
Monopar Therapeutics acting CMO sells $111 of stock, exercises options - Investing.com
Monopar Therapeutics (MNPR) director sells 4,090 shares near $110 - Stock Titan
Monopar Therapeutics (MNPR) director plans $906K share sale - Stock Titan
Monopar Therapeutics stock resistance test: Key levels to watch - tradersunion.com
Monopar Therapeutics (MNPR) acting CMO plans 1-share sale - Stock Titan
Monopar (NASDAQ: MNPR) director to sell 6,284 shares - Stock Titan
Monopar Therapeutics Inc Azioni (MNPR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Monopar Therapeutics Inc Azioni (MNPR) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| STARR CHRISTOPHER M | Director |
Oct 01 '26 |
Sale |
78.50 |
8,400 |
659,387 |
5,173 |
| CHRISTOPHER STARR | Director |
Oct 01 '26 |
Proposed Sale |
79.67 |
16,800 |
1,338,456 |
0 |
| Robinson Chandler | Chief Executive Officer |
Sep 24 '26 |
Option Exercise |
21.74 |
29,056 |
631,680 |
128,323 |
| CHANDLER ROBINSON | Director |
Sep 24 '26 |
Proposed Sale |
89.38 |
29,056 |
2,597,025 |
0 |
| Robinson Chandler | Chief Executive Officer |
Sep 24 '26 |
Sale |
88.00 |
29,056 |
2,556,851 |
99,267 |
| RIOUX PATRICE | Acting Chief Medical Officer |
Aug 26 '26 |
Sale |
111.26 |
1 |
111 |
5,065 |
| Tsuchimoto Kim R | Director |
Aug 26 '26 |
Sale |
111.39 |
4,090 |
455,567 |
7,396 |
| PATRICE RIOUX | Acting Chief Medical Officer |
Aug 26 '26 |
Proposed Sale |
110.82 |
1 |
111 |
0 |
| KIM TSUCHIMOTO | Director |
Aug 26 '26 |
Proposed Sale |
110.82 |
8,180 |
906,508 |
0 |
| RIOUX PATRICE | Acting Chief Medical Officer |
Aug 26 '26 |
Option Exercise |
0.01 |
1,380 |
7 |
5,066 |
5.91%
2.85%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):